News
NEWS

  • R&D

University of Tsukuba's research with which Celaid Therapeutics cooperates has been accepted by AMED

The research theme conducted by the University of Tsukuba and supported by Celaid Therapeutics has been selected by the Japan Agency for Medical Research and Development (AMED) as a "Bridging Research Program (preF)" for FY2022.

<Details of the AMED Adoption>
Announcement: "Bridging Research Program (preF)" in FY2022
Supporting Organization: University of Tsukuba
Title of R&D Project: Establishment of cord blood transplantation for acute leukemia using novel hematopoietic stem cell expansion technology
Principal Investigator :Professor Satoshi Yamazaki, University of Tsukuba

Link(Japanese)

Copyright© セレイドセラピューティクス - 細胞治療(造血幹細胞) , 2022 All Rights Reserved Powered by STINGER.